Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients

Table 3 Impact of tenofovir alafenamide on achieving a higher level of total cholesterol in chronic hepatitis B patients

Characteristic	TCHO, increased change (%) by using TAF compared with ETV1,2, OR (95%CI)	P value
5% higher than baseline	1.88 (1.11, 3.16)	0.019
10% higher than baseline	1.70 (0.94, 3.09)	0.081
15% higher than baseline	2.07 (0.99, 4.34)	0.055

¹All propensity score-matched models were adjusted for body mass index, age, sex, nonalcoholic fatty liver disease, cirrhosis, diabetes mellitus, hypertension, smoking, and drinking. The increased percentage change was presented by using tenofovir alafenamide (TAF) compared with entecavir (ETV).

²The increased change was transformation of the treatment effect coefficients in propensity score-matched models. CI: Confidence interval; OR: Odds ratio; TCHO: Total cholesterol.